BPD

Orphan designation: Azithromycin dihydrate Prevention of bronchopulmonary dysplasia, 14/01/2022 Positive

Retrieved on: 
Tuesday, April 9, 2024
Community, Diagnosis, Civil service commission, Bronchopulmonary dysplasia, Ureaplasma urealyticum infection, BPD, Prevalence, Protein, Disease, Infection, Clinical, Inflammation, Patient, Committee, Bacteria, EMA, IRIS, Update, Agency, European, COMP, European Commission, Marketing, Medicine, Pharmaceutical industry

Overview

Key Points: 
  • Overview
    This medicine was designated as an orphan medicine for the prevention of bronchopulmonary dysplasia in the European Union on 14 January 2022.
  • All medicines, including designated orphan medicines, must be authorised before they can be marketed and made available to patients in the EU.
  • The full list of orphan designations is available in the Community register of orphan medicinal products for human use.
  • EU register of orphan medicines
    The list of medicines that have received an orphan designation in the EU is available on the European Commission's website:

ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31, 2023

Retrieved on: 
Monday, February 26, 2024
Borderline personality disorder, HOPE, HDAC6, National Cancer Institute, EVOLUTION, CMT, Agitation, Data analysis, Convertible bond, ICIS, ALS, SCLC, Azacitidine, Duration, ICI, IIS, Sciatic nerve, Deficit spending, Paclitaxel, DSM-IV codes, Development, Genomics, ALS Association, FMS, LSD1, AML, Clinical Global Impression, MSKCC, Conference, Aggression, Safety, Biomarker, CNS, Venetoclax, CRADA, OHSU, MRD, Clinical trial, BPD, Measure (mathematics), IND, FCCC, Dor, Human, Innovation, EMA, Kabuki syndrome, NET, NCI, Aes, Glomus tumor, FDA, GST, Food, Platinum, Schizophrenia, Phase II, Charcot–Marie–Tooth disease, Medicine, Patient, BEST, Disease, Pharmaceutical industry

Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the fourth quarter.

Key Points: 
  • Dr Carlos Buesa, Oryzon’s Chief Executive Officer, said: “Oryzon continued with a strong path in its clinical programs in the fourth quarter.
  • Research and development (R&D) expenses were $3.9 and $16.6 million for the quarter and twelve months ended December 31, 2023, respectively, compared to $5.0 and $18.1 million for the quarter and twelve months ended December 31, 2022.
  • General and administrative expenses were $1.2 and $4.2 million for the quarter and twelve months ended December 31, 2023, respectively, compared to $1.2 and $4.8 million for the quarter and twelve months ended December 31, 2022.
  • Net losses were $1.4 and $5.0 million for the quarter and twelve months ended December 31, 2023, respectively, compared to $1.6 and $5.9 million for the quarter and twelve months ended December 31, 2022.

The Front Line Foundation Grants Death Benefits to Support the Families of Three Burnsville First Responders Killed on Duty

Retrieved on: 
Monday, February 19, 2024
Violence, Police, News, SWAT, National Guard, Army, Emergency medical technician, Grief, Death, Hockey, Law enforcement, BPD, Life insurance

MINNEAPOLIS, Feb. 19, 2024 /PRNewswire-PRWeb/ -- The Front Line Foundation (TFLF) announced today that it is giving a total of $60,000 in death benefits to the families of Burnsville Police Officers, Paul Elmstrand and Matthew Ruge, both 27 and Adam Finseth, 40, a firefighter and paramedic for the city who were all killed in the line duty on the morning of February 18 while reporting to a domestic violence and hostage crisis in the city.

Key Points: 
  • Each of the three families will receive $20,000 in death benefits to support them prior to full death benefits being paid out.
  • The Foundation's mission is to bridge the gap between the death and benefits being paid, which can help families with ongoing expenses.
  • The Foundation also provides support in the purchase of tactical equipment for first responders which is not included in department budgets.
  • To date The Front Line Foundation has paid out $510,000 in death benefits and equipment funding since it was founded in 2018.

Blue Tide Environmental Completes Initial Phase of State-of-the-Art Base Oils Re-Refining Facility

Retrieved on: 
Wednesday, February 14, 2024
UMO, Shell plc, Carbon footprint, Tailwater, Lubricant, Shell, VGO, Hydrodesulfurization, Lake-effect snow, BPD, Partnership, Oil

DALLAS, Feb. 14, 2024 /PRNewswire/ -- Blue Tide Environmental ("Blue Tide"), an environmental company focused on developing a network of used motor oil ("UMO") re-refining facilities across North America and portfolio company of Tailwater Capital LLC ("Tailwater"), today announced the completion of the first phase of its base oils re-refinery located in Baytown, Texas ("Baytown Facility").

Key Points: 
  • DALLAS, Feb. 14, 2024 /PRNewswire/ -- Blue Tide Environmental ("Blue Tide"), an environmental company focused on developing a network of used motor oil ("UMO") re-refining facilities across North America and portfolio company of Tailwater Capital LLC ("Tailwater"), today announced the completion of the first phase of its base oils re-refinery located in Baytown, Texas ("Baytown Facility").
  • "We are thrilled to see this cutting-edge facility officially come online, as it marks a pivotal milestone for Blue Tide," said Mark Bouldin, Chief Executive Officer of Blue Tide.
  • The second phase of the project is now underway, which includes constructing a hydrotreater at the Baytown Facility to upgrade the VGO into superior-quality Group II+ base oils.
  • "Today, we celebrate the start-up of the initial phase of Blue Tide's re-refining facility and are excited to complete the next phase of the project to produce high-performance re-refined base oils made with a lower carbon footprint," said David Cecere, Partner at Tailwater.

Retired FBI Agent Shares His Inspiring World Travel and Involvement in High Profile Cases

Retrieved on: 
Thursday, February 8, 2024
African Americans, Crime, Life, Pan Am Flight 103, BBC, FBI, BPD, Dream, Pan Am, Pond, Sky Television

NAPLES, Fla., Feb. 8, 2024 /PRNewswire-PRWeb/ -- Reminiscing on his career, author, former police officer, and FBI agent Phillip Reid came to the realization that over his 36 years in law enforcement, he had achieved the majority of his dreams and goals with the help of his chosen career. With his book, "Three Sisters Ponds: My Journey from Street Cop to FBI Senior Executive – from Baltimore to Lockerbie, Pakistan and Beyond," he wants to inspire others to chase their dreams, and even consider a career of their own in law enforcement.

Key Points: 
  • From his humble beginnings to his time patrolling the streets of Baltimore, to traveling the world as an FBI agent, Reid chronicles how he reached his dreams and goals.
  • In his time as an accomplished FBI agent, he had the opportunity to work on the Pan Am Flight 103 bombing investigation as part of their international extra-territorial terrorism.
  • I am grateful to have been able to bring those criminals, and others, to justice during my time with the FBI."
  • "Three Sisters Ponds: My Journey from Street Cop to FBI Senior Executive – from Baltimore to Lockerbie, Pakistan and Beyond"

Real-World Data on Human Milk-Based Fortification Reveals Limitations of Protocol Designs of Two RCTs

Retrieved on: 
Tuesday, February 6, 2024
Growth, Mortality, Bronchopulmonary dysplasia, Hospice and palliative medicine, NEC, Standard of care, BPD, NICU, Disease, Patient, Incidence, Sepsis, RCT, Clinical study design, Isabella Tree, BMBF, Risk, Exclusive, Vulnerable, FAAP, Birth weight, Standard, Necrotizing enterocolitis, Gestational age, Hospital, Dietary supplement

DUARTE, Calif., Feb. 6, 2024 /PRNewswire/ -- Optimizing nutrition for premature infants remains an important focus in neonatal care. More than 20 peer-reviewed studies of 5,000+ preterm infants demonstrated that, compared to bovine milk-based fortifiers (BMBF), Prolacta Bioscience's human milk-based fortifiers (HMBF) improve growth and development1-7 and provide clinically significant reductions in comorbidities.1,2,8-20 The health benefits from the use of HMBF have also shown significant annual cost savings for hospitals.8 More than 100,000 critically ill and preterm infants have received Prolacta's human milk-based nutritional products.21

Key Points: 
  • While the RCTs were intended to provide a head-to-head comparison between fortifier products, the feeding protocols fundamentally differed.
  • HMBF recommendations for best outcomes regarding the day fortification should begin and the speed at which feeds are advanced were not followed in either study.
  • Given these known risks, randomizing extremely premature infants to day-one fortification with BMBF would unjustly endanger this vulnerable patient population.
  • Extensive real-world data affirm EHMD adoption enables critical health improvements for premature infants and major cost reductions for hospitals.

Phillips 66 Delivers Strong 4Q 2023 Results, Advances Strategic Priorities

Retrieved on: 
Wednesday, January 31, 2024
Professional Services, Chemicals, Plastics, Oil, Gas, Manufacturing, Energy, Finance, BPD, Transport, QatarEnergy, Public expenditure, Carbon, Investment, DCP Midstream Partners, Phillips 66, Midstream, Webcast

Phillips 66 generated $2.2 billion in cash from operations in the fourth quarter of 2023.

Key Points: 
  • Phillips 66 generated $2.2 billion in cash from operations in the fourth quarter of 2023.
  • During the fourth quarter, Phillips 66 funded $634 million of capital expenditures and investments, $1.2 billion of share repurchases and $457 million in dividends.
  • Phillips 66 is executing its strategic priorities to increase mid-cycle adjusted EBITDA by $4 billion to $14 billion by 2025 and grow shareholder distributions.
  • Members of Phillips 66 executive management will host a webcast at noon ET to provide an update on the company’s strategic initiatives and discuss the company’s fourth-quarter performance.

FedTec Launches With Expanded Leadership

Retrieved on: 
Tuesday, January 23, 2024
Senior, FDIC, Bureau, DOE, BPD, Growth, DHS, Federal, Ram, CFPB, IRS, USPS, Government, FMS, FRB, Booz Allen Hamilton, Management

Reston, VA, Jan. 23, 2024 (GLOBE NEWSWIRE) -- FedTec, a leading provider of technology and digital services to federal agencies, announced Tuesday, January 23rd 2024 it is rebranding the company from FreeAlliance, LLC to FedTec, aided by key leadership acquisitions.

Key Points: 
  • Reston, VA, Jan. 23, 2024 (GLOBE NEWSWIRE) -- FedTec, a leading provider of technology and digital services to federal agencies, announced Tuesday, January 23rd 2024 it is rebranding the company from FreeAlliance, LLC to FedTec, aided by key leadership acquisitions.
  • Under the visionary leadership of CEO and President, Mona Kaur , FedTec is set to redefine the future of federal digital solutions, infrastructure services, and cybersecurity.
  • Prior to joining FedTec, he dedicated 19 years to Booz Allen, where he held the position of Senior Vice President.
  • For more information about FedTec and its transformation, please visit FedTec.com.

ORYZON to Host KOL Event on Phase IIb PORTICO Topline Study Results of Vafidemstat in Borderline Personality Disorder on January 25, 2024

Retrieved on: 
Friday, January 19, 2024
Vall d'Hebron University Hospital, Teaching hospital, Borderline personality disorder, Yale school, BPD, Yale School of Medicine, MD, Vall, Genomics, Webcast, Doctor of Philosophy, KOL, Phase

To register for the event, click here .

Key Points: 
  • To register for the event, click here .
  • The event will feature a brief review of the topline results of the Phase IIb PORTICO study, then a discussion with:
    KOL Marc Ferrer, MD, PhD (Vall d'Hebron University Hospital), PORTICO E.U.
  • KOL Sarah Fineberg, MD, PhD (Yale School of Medicine), a Psychiatrist not involved with PORTICO to provide an independent clinician’s perspective on the potential clinical and real-world implications for the results.
  • A replay of the webcast will be available on the company’s website after the event.

Chiesi Group and Oak Hill Bio announce License and Development Agreement to develop, manufacture, and commercialize OHB-607, a potentially transformative neonatal therapy

Retrieved on: 
Tuesday, January 9, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Development, Guggenheim Partners, BPD, Mother, Neonatology, Gestational age, Place of birth, License, Risk, Disease, Premature, Bronchopulmonary dysplasia, Pharmaceutical industry

OHB-607 is a recombinant version of insulin-like growth factor-1 (IGF-1), a key driver of fetal growth and development, and its binding protein, IGFBP-3.

Key Points: 
  • OHB-607 is a recombinant version of insulin-like growth factor-1 (IGF-1), a key driver of fetal growth and development, and its binding protein, IGFBP-3.
  • For the developing fetus, mothers are the primary source of IGF-1.
  • Clinical studies conducted to date have demonstrated OHB-607’s potential to significantly reduce the risk of severe BPD1.
  • Their deep expertise in neonatology will help to rapidly advance this promising therapy to patients.”
    Guggenheim Securities LLC acted as exclusive financial advisor to Oak Hill Bio and Goodwin Procter LLP served as its legal advisor.